Article Text

Download PDFPDF
Screening for coeliac disease in patients fulfilling the Rome II criteria for irritable bowel syndrome in a secondary care hospital in The Netherlands: a prospective observational study
  1. Egbert-Jan van der Wouden1,
  2. G Frits Nelis2,
  3. Juda Vecht2
  1. 1Department of Gastroenterology, Isala Klinieken, Zwolle, The Netherlands
  2. 2Department of Gastroenterology, Isala Klinieken, Zwolle, The Netherlands
  1. Correspondence to:
    Dr E J van der Wouden
    Department of Gastroenterology, University Medical Center Groningen, P O Box 30001, 9700 RB, Groningen, The Netherlands; e.j.van.der.wouden{at}int.umcg.nl

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Irritable bowel syndrome is the most commonly diagnosed gastrointestinal condition and affects a large proportion of the population in the West.1 Several guidelines suggest that in typical patients with no alarm symptoms or signs, apart from routine laboratory tests, no additional tests are necessary.2 Coeliac disease, however, may present with symptoms suggestive of irritable bowel disease.3 Several studies suggested that screening for coeliac disease in patients with symptoms suggestive of irritable bowel disease might be cost-effective.4–7 We, therefore, started to routinely screen patients with typical irritable bowel disease symptoms for coeliac disease using antiendomysial antibodies.

All patients referred to three doctors at the outpatient gastroenterology department of our hospital between November 2002 and …

View Full Text

Footnotes

  • Competing interests: None.

Linked Articles